Key result
ACS patients successfully self-acquire KardiaMobile ECGs, yielding ~89% clean and interpretable tracings.
Why the study?
Remote cardiac monitoring may supplement symptom appraisal and reduce delayed care-seeking in ACS, but the ability of ACS patients to remotely self-acquire a derived 12-lead ECG using a KardiaMobile 6L device was unknown.
Can hospitalized patients with suspected acute coronary syndrome self-acquire diagnostic quality derived 12-lead ECGs using a KardiaMobile 6L remote monitoring device and self-report symptoms?
Observational (n=30)
Cardiologist blinded to clinical data
Can hospitalized patients with suspected acute coronary syndrome self-acquire diagnostic quality derived 12-lead ECGs using a KardiaMobile 6L remote monitoring device and self-report symptoms?
Hospitalized patients with suspected ACS can feasibly self-acquire interpretable derived 12-lead ECGs capable of showing ischemic changes and self-report symptoms using mobile health technology.
Answers are grounded in this paper and cite their sources.
Supports feasibility of self-acquired ECGs in hospitalized ACS; hypothesis-generating for remote monitoring before clinical adoption.
BACKGROUND: Acute coronary syndrome (ACS), one of the leading causes of death in the United States, requires rapid evaluation, diagnosis, and therapy initiation to reduce morbidity and mortality. Delayed care-seeking remains the primary reason that patients with ACS fail to receive timely treatment. Remote cardiac monitoring may supplement individuals' symptom appraisal and reduce delays. However, ACS patients' ability to remotely self-acquire an electrocardiogram (ECG) is unknown. OBJECTIVE: To evaluate whether hospitalized patients with suspected ACS can acquire a derived 12-lead (L) ECG using a KardiaMobile 6L remote cardiac monitoring device. METHODS: Participants were hospitalized patients aged >21 years at high risk for ischemic events (ACS diagnosis with a History, ECG, Age, Risk factors, and Troponin score >3, ie, moderate to high risk for cardiac event) who owned an iPhone. Research assistants trained participants to use mobile applications to (1) acquire an ECG at least once daily during their hospitalization and (2) document symptoms using the ACS Symptom Checklist. A cardiologist blinded to clinical data compared ischemic markers (eg, ST-elevation, ST-depression, and T-wave inversion) on KardiaMobile 6L derived 12L ECGs with hospital-based 12L ECGs. RESULTS: We enrolled 30 participants (mean age 64.2 ± 11.2 years, 30.0% female, 73.3% White). All participants acquired at least 1 remote cardiac device ECG. A cardiologist classified 88.9% as clean and interpretable; the remainder were noisy but interpretable. Ischemic markers were present on both patient-acquired and hospital-based ECGs. All participants submitted at least 1 Symptom Checklist. CONCLUSIONS: Hospitalized patients with suspected ACS can self-acquire a 6L ECG and self-report symptoms, and derived 12L ECGs can detect signs of ischemia (eg, ST-elevation). Future studies should examine ECG acquisition and transmission from home and remote evaluation for early ischemia detection and response.
No takes yet. Share an insight, caveat, or question.
Zègre‐Hemsey et al. (2026) conducted an observational in Suspected acute coronary syndrome (ACS) (n=30). Self-acquisition of derived 12-lead ECG using KardiaMobile 6L remote cardiac monitoring device and ACS Symptom Checklist reporting vs. Hospital-based 12-lead ECG was evaluated on Feasibility and interpretability of self-acquired derived 12-lead ECGs and presence of ischemic markers.
Synapse has enriched 10 related papers. Consider them for comparative context: